With a strong blow of international biosimilar access, Indian-based Biocon Biologics subsidiary of Biocon Ltd has released several market access agreements in the U.S. for its recently approved biosimilar, Yesintek (ustekinumab-kfce).
Yesintek, a US-approved biosimilar of Stelara® (ustekinumab), is indicated for the treatment of many autoimmune conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Growing Access to More Than 100 Million Lives
Based on Biocon’s recent regulatory filing, the market access deals signed to date account for more than 100 million covered lives across several U.S. insurance plans — an important milestone towards commercializing Yesintek in one of the most competitive health care markets in the world.
This business achievement makes a more cost-effective and clinically validated disease management program for chronic immune-mediated diseases available to more patients while reducing the cost of care without sacrificing efficacy.
What Is Yesintek?
Yesintek (ustekinumab-kfce) is a biosimilar of Stelara, created to provide similar therapeutic outcomes in the treatment of moderate to severe autoimmune diseases. Stelara, from Janssen Pharmaceuticals, is a highly used biologic in the immunology field, so the introduction of Yesintek is timely and significant.
With U.S. FDA regulatory approval and increasing reimbursement coverage, Biocon Biologics is placing Yesintek as a cost-effective, high-quality option in a biosimilar-starved market.
Building Biocon Biologics’ U.S. Footprint
The U.S. market access victory for Yesintek is a testament to Biocon Biologics’ expanding footprint and strength in the global biosimilars market. The company has been building its presence incrementally in North America by making targeted acquisitions and gaining regulatory approvals.
With biosimilars increasingly being widely accepted by payers, providers, and consumers, Biocon’s move demonstrates the company’s intent to compete on an equal footing with multinational drug firms in the specialty biologics business.
Implications for Healthcare and Patients
The incorporation of Yesintek into large U.S. health plans can mean more convenient treatment access, particularly for individuals with significant out-of-pocket expenditures. Since most chronic autoimmune conditions often necessitate extended therapy, the presence of affordable biosimilars such as Yesintek can substantially reduce patients’ and health systems’ financial burdens.
FAQs:
- What is Yesintek?
Yesintek (ustekinumab-kfce) is a biosimilar medication produced by Biocon Biologics. It is utilized for the treatment of autoimmune conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. - What is a biosimilar?
A biosimilar is a biologic health product that is highly similar to an already approved reference product—here, Stelara (ustekinumab)—and free from clinically significant differences in safety, purity, or potency. - Who manufactures Yesintek?
Yesintek is manufactured by Biocon Biologics, a subsidiary of Biocon Ltd, which is an Indian-headquartered global biopharmaceutical firm. - What is the reference drug similar to which Yesintek is?
Yesintek is a biosimilar of Stelara®, a biologic medicine developed by Janssen Pharmaceuticals that has received approval for the treatment of multiple autoimmune conditions. - Is Yesintek approved by the U.S. FDA?
Yes, Yesintek was granted regulatory approval by the U.S. Food and Drug Administration (FDA) for commercial sale for the treatment of multiple immune-mediated conditions. - What does the market access agreement include?
The partnerships make Yesintek accessible on U.S. health insurance plans covering over 100 million insured lives and viable and reimbursable to a vast patient base. - Why is market access critical for biosimilars?
Market access guarantees that biosimilars such as Yesintek are included in insurance formularies, thus becoming more affordable and available to patients and prescribers. - How will patients be enhanced by the availability of Yesintek?
Patients will be able to access cheaper treatment for chronic autoimmune diseases, which are generally costly to treat using branded biologics. - Is Yesintek equivalent to Stelara?
Yes, biosimilars will have to prove high similarity and no clinically relevant differences from the reference product in efficacy, safety, and quality to gain FDA approval. - What are the implications for Biocon Biologics?
This milestone firmly places Biocon Biologics in the biosimilar market in the U.S. and its role as a global biologics and affordable healthcare solutions player.
Conclusion
Biocon Biologics’ success in obtaining access to more than 100 million covered lives in the United States for its Stelara biosimilar, Yesintek, is a landmark moment in biosimilar adoption and the cost of world health. With growing demand for biologics, this action brings the door wider to greater access and a competitive market in immunology therapies.
Disclaimer
Barawakar does not provide financial advice and the information on the website www.Barawakar.com is only for general use. Users of Barawakar accept full responsibility in the possibility of losing capital. Barawakar strives to provide correct information, but offers no guarantees regarding the accuracy or completeness of data given.
In case of any investments planning, make sure to seek professional counsel or do amplify your own research. The www.barawakar.com website is available to users without warranties on availability or functionality. By using this website, you accept the terms of these conditions.
For any questions, feel free to reach out to us.